Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer

Editorial Material Oncology

Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?

Gulam A. Manji

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Oncology

Neoadjuvant therapy for pancreatic cancer

Christoph Springfeld et al.

Summary: This article discusses the treatment strategies for pancreatic ductal adenocarcinoma (PDAC), including surgical resection and systemic chemotherapy. Neoadjuvant chemotherapy may improve the survival outcomes of patients with borderline-resectable PDAC. For patients with unresectable PDAC, undergoing chemotherapy may lead to surgical resection and improved survival outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer A Randomized Clinical Trial

Thierry Conroy et al.

Summary: The 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma.

JAMA ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Spatially confined sub-tumor microenvironments in pancreatic cancer

Barbara T. Grunwald et al.

Summary: Through large-scale integration of histology-guided regional multiOMICs with clinical data and patient-derived preclinical models, we identified distinct subTMEs in the human pancreatic tumor microenvironment (TME) that are linked to tumor immunity, subtypes, differentiation, and treatment response. Reactive subTMEs rich in coordinated fibroblast communities were immune hot, while matrix-rich deserted subTMEs harbored fewer activated fibroblasts but showed chemoprotective features. These subTMEs originated in fibroblast differentiation trajectories and produced patient-specific heterogeneity tightly linked to malignant biology.

CELL (2021)

Add to Collection

Article Medicine, General & Internal